Recent surveys indicate a decline in obesity rates across the United States, sparking discussions about the potential impact of weight loss drugs like Ozempic, Wegovy, and Mounjaro. These medications, part of the GLP-1 drug class, are believed to contribute to this positive trend. However, despite the overall decrease in obesity statistics, certain states such as Nevada and Kentucky continue to report alarming obesity levels, prompting calls for increased health initiatives. While more states are beginning to show progress in managing obesity, significant disparities and the prevalence of severe obesity remain pressing concerns nationwide.